Login to Your Account

Other News To Note

Wednesday, December 14, 2011
• Beactica AB, of Uppsala, Sweden, inked an agreement with Almac Discovery Ltd., of Craigavon, Northern Ireland, for the use of its drug discovery platform, Sprint, to identify high-quality fragment hits against undisclosed targets of therapeutic interest to Almac. Beactica specializes in surface plasmon resonance biosensor-based small-molecule interaction analysis and partnerships for fragment-based lead generation using the Sprint platform.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription